An estimated 60% of people have amyloid plaques in their brains by the end of their lifespans, but only one-fifth of amyloid-positive individuals will develop dementia, according to Alberto J ...

Clumps or plaques of the protein beta-amyloid in the brain are a hallmark of a type of dementia called Alzheimer’s disease. When beta-amyloid plaques form, they disrupt communication between ...

Beta-amyloid plaques are considered a hallmark of Alzheimer’s disease, but they’re not the sole cause of the disease and its symptoms. Alzheimer’s is a complicated disease that experts are ...

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can ...

The team focused on Aβ42, a form of the amyloid beta with 42 amino acids that is commonly found in people with Alzheimer's disease. The researchers used three techniques in their work.

In this adapted excerpt from his new book “Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over Alzheimer’s ...

Yet, he uses patent sensationalism to promote his book, with monikers of “amyloid mafia,” “cabal,” and “Church of the Holy Amyloid.” The hypocrisy is profound. — Fred Haberle.

If scientists can prove that reducing amyloid plaques slows down thinking and memory problems in Alzheimer’s disease, a vaccine against beta-amyloid may be the next step. Several potential ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli Lilly (NYSE:LLY) is looking at other targets as well. The drugmaker's ...